Cancer Treatment Eased by Eric Lefkofsky

Cancer is currently the most dangerous disease. Eric Lefkofsky co-founded a company called Tempus, mainly focused on using genomic sequencing to help customize cancer treatments. Recently, the Chicago based company, Tempus, announced that it raised $ 70 million from New Enterprise Associates and Revolution Growth in its series C funding. This financing will sum up the total amount raised since Tempus was established in 2015 to $ 130 million and more information click here.

Eric Lefkofsky who serves as the CEO and his business partner, Brad Keywell take part significantly in every fundraising round for Tempus. Last year, Eric told Crain’s Chicago that he is willing to invest up to $ 100 million in the business. Investors New Enterprise Associates and Revolution Growth have also funded companies like stock trading app Robinhood and salad restaurant Sweetgreen respectively among others and Eric on Facebook.

After many years in the tech industry, Eric Lefkofsky ventured into the healthcare when a loved one was diagnosed with breast cancer. During treatment, Eric realized there is short of technology on how data collection was conducted. Tempus was then established, which has created platforms of technology that compile genomic and clinical data from cancer patients making it easier for doctors to personalize the treatment.

Datasets have been small and disorganized but with Tempus massive amount of molecular and clinical data are amassed benefiting the patient. Last year Tempus announced partnerships withDuke University School of medicine, the Mayo Clinic, Cleveland Clinic and many others. Tempus looks forward to building the world’s most extensive library of clinical and molecular data to customize and improve cancer treatment and Eric’s lacrosse camp.

Eric Lefkofsky was born in Southfield, Michigan but most of his adult life was in Chicago. He graduated with honors from the University of Michigan. Later, he attained his Juris Doctor from the University of Michigan, Law School. He also serves as the chairman of Groupon, and co-founder of Uptake Technologies.

Together with Brad Keywell, they have established several companies like VC fund Lightbank. Eric has committed staff members at Tempus who work hard to provide care to cancer patients. Eric and his wife established Lefkofsky Foundation to support organizations globally. Caring for patients and loved ones is the motive of Tempus and http://www.chicagobusiness.com/article/20161001/ISSUE01/310019995/can-eric-lefkofsky-save-your-life.

Rutgers Cancer Institute Establishes Omar Boraie Chair

In a bid to propel research on precision medicine, the Rutgers Cancer Institute (http://patch.com/new-jersey/newbrunswick/omar-boraie-chair-genomic-science-established-rutgers-cancer-institute) has established the Omar Boraie Chair in Genomic Science.

Genomic science is an important part of the higher education, and its advancement is crucial. That is the reason why the Institute established the 18 chair challenge campaign to raise funds for the advancement of the discipline.

Omar Boraie was one of the 18 chairs that made a pledge for supporting the Institute. He pledged $1.5 million towards the campaign. That is what has led to the establishment of a chair under his name. Dr. Shridar Ganesan, MD, Ph.D.an associate director for the translational science have been named to this chair. He is also the principal investigator of the precision medicine.

It is a new medical approach that will analyze and also treat the cancer cells on a genetic level. This will help the medical personnel to prescribe individualized therapies.

The former president of the United States Barack Obama announced the launch of a National Precision Medicine Initiative during one of his State of the Nation address. This initiative will be focused on finding a cure for cancer and other terminal diseases.

There are different centers that are using the next-generation treatment. However, it is only Rutgers Cancer Institute that is dealing with genomic science and precision medicine. Genomic science has played an important role in the establishing treatments for the rare cancer tumors. Precision medicine will help in the classification of the cancer tumors in subgroups with similar characteristics.

Boraie said that he is hopeful that his pledge will make a significant impact in the Institute. He supports the research being done to establish a therapy treatment for the patients who are no longer responding to medication.

The Rutgers Cancer Institute is the first State-owned National Cancer Institute which is Comprehensive Cancer Center. The Institute is dedicated to improving the treatment of the different cancer tumors. The State University of New Jersey and the Cancer Institute of New Jersey are part of the Institute.

The scientists in the institute bring their research into reality by using the translational approach to their research.

This are article first published on Newswise.com http://newswise.com/articles/omar-boraie-chair-in-genomic-science-established-at-rutgers-cancer-institute